Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELOVL3 small interfering RNA
- Development stage
- Preclinical
- Lead developer
- Toho University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ELOVL3 small interfering RNA is a double-stranded RNA molecule designed to silence the expression of the ELOVL3 (elongation of very long chain fatty acids-like 3) gene via RNA interference. ELOVL3 is an endoplasmic reticulum-bound enzyme that catalyzes the elongation of saturated and monounsaturated very-long-chain fatty acids (VLCFAs). In preclinical research conducted by Toho University, ELOVL3 siRNA was investigated for its potential to mitigate sleep deprivation-induced hepatic steatosis and improve glucose tolerance by suppressing hepatic lipid accumulation.
- Other names
- ELOVL3 siRNAELOVL-3 siRNAELOVL 3 siRNAelovl3-specific siRNAelovl-3-specific siRNAelovl 3-specific siRNAelovl3-specific small interfering RNAelovl-3-specific small interfering RNAelovl 3-specific small interfering RNA
02
Targets
PEDF-R (Pigment epithelium-derived factor receptor)LIPE (Hormone-sensitive lipase)MGL (Methionine gamma-lyase)PPARG (Peroxisome proliferator-activated receptor gamma)ELOVL (Very-long-chain fatty acid elongase family)
Beyond the preview
Go deeper on ELOVL3 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELOVL3 small interfering RNA.